NASDAQ: ADAG - Adagene Inc.

Yield per half year: -12.8%
Sector: Healthcare

Share chart Adagene Inc.

Financial Markets by TradingView

About

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers.

More details
The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.00048
EBITDA -0.0167
Число акций ао 0.04379 млрд
P/S 30.25
P/BV 1.966
EV/EBITDA 5.39
Цена ао 2.51
ISIN US0053291078
Сайт https://www.adagene.com
Change price per day: 0% (2.86)
Change price per week: +5.54% (2.71)
Change price per month: +27.11% (2.25)
Change price per 3 month: +10.21% (2.595)
Change price per half year: -12.8% (3.28)
Change price per year: +142.37% (1.18)
Change price per year to date: +93.24% (1.48)


All parameters ⇨

Underestimation

Title Value Grade
P/S 4.04 4
P/BV 1.0364 9
P/E 0 0
EV/EBITDA 0.5575 10
Total: 5.38

Efficiency

Title Value Grade
ROA, % -14.13 0
ROE, % -24.66 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.8577 10
Total: 8.8

Growth impulse

Title Value Grade
Yield Revenue, % 3670.83 10
Yield Ebitda, % 55.69 7
Yield EPS, % -2.08 0
Total: 5.6
More

Institutions Volume Share, %
Wuxi Apptec Co., Ltd. 4225696 9.58
HSG Holding Ltd. 1343364 3.05
Artal Group S.A. 1000000 2.27
General Atlantic, L.P. 264000 0.6
Morgan Stanley 146721 0.33
FMR, LLC 124962 0.28
Geode Capital Management, LLC 10309 0.02
Rhumbline Advisers 8965 0.02
Osaic Holdings Inc 538 0
Qube Research & Technologies Ltd 47 0

ETF Share, % Profitability for 1 year, % Dividends, %
iShares MSCI EAFE Min Vol Factor ETF 1.35 14.98 2.97
WisdomTree Europe Hedged Equity Fund 2.15 32.81 3.06
Pacer Developed Markets International Cash Cows 100 ETF 2.07 38.96 3.68
iShares MSCI Netherlands ETF 3.47 50.87 1.78
American Century Quality Diversified International ETF 1.1 26.08 2.93
Hartford Multifactor Developed Markets (ex-US) ETF 0.98 24.23 4.08



Head Job title Payment Year of birth
Dr. Peter P. Luo Ph.D. Co- Founder, Chairman, CEO and President of R&D N/A 1966 (58 years)
Mr. Man Kin Tam M.B.A. CFO & Director N/A 1977 (47 years)
Dr. Jc Xu M.D., Ph.D. Chief Scientific Officer N/A 1965 (59 years)
Ms. Ami Celeste Knoefler Vice President of Investor Relations & Corporate Communications N/A
Ms. Ling Zhou Head of Human Resources N/A
Dr. Qinghai Zhao Chief Manufacturing Officer N/A 1961 (63 years)
Ms. Yan Li M.B.A. Senior VP of Bioinformatics & Information Technology and Director N/A 1975 (49 years)
Ms. Xiaohong She Senior VP & Head of Clinical Operations N/A 1967 (57 years)
Dr. Guizhong Liu Ph.D. Senior Vice President of Early Drug Discovery N/A 1971 (53 years)
Mr. Alexander Goergen VP & Head of Business Development N/A 1987 (37 years)

Address: China, Suzhou, Building C14 - open in Google maps, open in Yandex maps
Website: https://www.adagene.com